Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $0.47 in the prior trading day, Harvard Bioscience Inc (NASDAQ: HBIO) closed at $0.48, up 3.67%. In other words, the price has increased by $3.67 from its previous closing price. On the day, 0.68 million shares were traded. HBIO stock price reached its highest trading level at $0.487 during the session, while it also had its lowest trading level at $0.4668.
Ratios:
Our goal is to gain a better understanding of HBIO by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.89 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.88. For the most recent quarter (mrq), Quick Ratio is recorded 0.41 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 2.75 whereas as Long-Term Debt/Eq ratio is at 0.45.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HBIO now has a Market Capitalization of 21521928 and an Enterprise Value of 57437928. For. The Stock, the TTM Price-to-Sale (P/S) ratio is 0.24 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at 0.647 whereas that against EBITDA is 16.235.
Stock Price History:
The Beta on a monthly basis for HBIO is 1.54, which has changed by -0.82545453 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, HBIO has reached a high of $2.94, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of. The Stock is 0.63%, while the 200-Day Moving Average is calculated to be -45.42%.
Shares Statistics:
. The Stock has traded on average 1.02M shares per day over the past 3-months and 1691130 shares per day over the last 10 days, according to various share statistics. A total of 44.53M shares are outstanding, with a floating share count of 37.92M. Insiders hold about 14.85% of the company’s shares, while institutions hold 43.69% stake in the company. Shares short for HBIO as of 1756425600 were 757327 with a Short Ratio of 0.74, compared to 1753920000 on 1316218. Therefore, it implies a Short% of Shares Outstanding of 757327 and a Short% of Float of 1.8399999999999999.
Earnings Estimates
The current assessment of Harvard Bioscience Inc (HBIO) involves the perspectives of 2.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.04, with high estimates of $0.04 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.03 and $0.02 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is $0.12, with 2.0 analysts recommending between $0.15 and $0.1.
Revenue Estimates
2 analysts predict $20M in revenue for the current quarter. It ranges from a high estimate of $21M to a low estimate of $19M. As of the current estimate, Harvard Bioscience Inc’s year-ago sales were $21.97MFor the next quarter, 2 analysts are estimating revenue of $23.1M. There is a high estimate of $23.4M for the next quarter, whereas the lowest estimate is $22.8M.
A total of 2 analysts have provided revenue estimates for HBIO’s current fiscal year. The highest revenue estimate was $86.6M, while the lowest revenue estimate was $84M, resulting in an average revenue estimate of $85.3M. In the same quarter a year ago, actual revenue was $94.14MBased on 2 analysts’ estimates, the company’s revenue will be $91.5M in the next fiscal year. The high estimate is $95.6M and the low estimate is $87.4M.
